Navigation Links
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Date:12/1/2011

pleted.  Clinical investigators include Dr. Howard Burris at Sarah Cannon Research Institute, Dr. Roger Cohen at Hospital of the University of Pennsylvania/Abramson Cancer Center and Dr. Keith Flaherty at Massachusetts General Hospital.

About MGA271
MGA271 is a humanized IgG1/kappa monoclonal antibody that recognizes human B7-H3, a novel member of the B7 family of immune regulators.  B7-H3 is an attractive target for immunotherapy, as it is over-expressed in a variety of solid tumors, including prostate, pancreatic, renal cell, ovarian, colorectal, gastric, bladder, and non-small cell lung cancers as well as melanoma. MGA271 has been Fc-optimized using MacroGenics' proprietary Fc-engineering platform to further augment its tumor killing activity. The product's Fc region imparts increased affinity for the human activating Fc-gamma receptor IIIA (Fc-gamma RIIIA, CD16A) and decreased affinity for the inhibitory Fc-gamma RIIB (CD32B).

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. which employ its DART technology.  For more information about MacroGenics, ple
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
2. MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
3. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DARTâ„¢-Based Antibody Therapeutics
4. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
5. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
8. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
9. Zimmer to Establish Asia-Pacific Research and Development Center
10. vRad Selected by Abbeville Area Medical Center for PACS Replacement
11. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
... BOTHELL, Wash., June 25 Verathon(R), the maker of BladderScan(R) ... company,s selection, for the third year in a row, as ... State. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ) , ... for 16th "Best Company To Work For" in the mid-size ...
... Association said Thursday that pop singer Michael Jackson,s death at ... arrest, which kills nearly 300,000 Americans each year and is ... cardiac arrest (SCA) is the result of an electrical disruption ... It can strike seemingly healthy individuals without warning, including ...
... warns of potential shortage of one pain reliever , THURSDAY, ... and drug ingredients at a Michigan-based manufacturer by the U.S. ... a particular type of pain reliever, the agency said on ... products from plants run by Caraco Pharmaceutical Laboratories Ltd in ...
... ... , ... (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a 53-year-old ... identical. Which employee will return to work sooner? Is there anything you can do ...
... Providence Service Corporation (Nasdaq: PRSC ) today ... Inc., have certified the voting results of the Company,s ... preliminary results reported by Providence on June 15, 2009. ... a wide margin, re-elected to the Providence Board of ...
Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Recognized, Third Year in a Row, as Outstanding Workplace in Washington State 2Health News:FDA Seizes All Drugs From Generics Maker 2Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 2Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: